Document Detail

Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.
MedLine Citation:
PMID:  20979696     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: Concurrent chemoradiotherapy for cervical carcinoma develops rapidly and has become a common and standard therapy in recent years. Both the local control rate and survival rate of patients were increased and the risk of death fell by 30%-50%. This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment compliance of the patients with advanced cervical squamous cell carcinoma.
METHODS: A total of 156 patients with stage IIa-IIIb cervical squamous cell carcinoma were randomly divided into the concurrent chemoradiotherapy group (experimental group) and radiotherapy group (control group). Intracavity and external beam radiation therapy were administered. At point A, 40-48 Gy were given by 10-12 fractions; at point B, 46-50 Gy were given by 23-25 fractions. In the same time, experimental group was treated by cisplatin (DDP, 40 mg) on day 1, repeated every week. Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy.
RESULTS: For the experimental and control groups, the objective response rates were 88.61% and 75.32%, 1-year survival rates were 88.57% and 70.77%, 1-year local control rates were 81.43% and 64.62%, 3-year survival rates were 82.14% and 57.69%, and 3-year local control rates were 75.00% and 46.15%, with significant differences (P<0.05). Quality of life of all patients were significantly improved after treatment (P<0.05).
CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and long-term survival and local control rates of patients, improve the quality of life, and the toxicity can be tolerated.
Shun Wang; Da-Shui Zhang; Tao Pan; Sha Liu; Ming-Kun Wang
Related Documents :
9767616 - Non-surgical therapy for patients with advanced non-small cell lung cancer.
8746886 - A bayesian analysis of bivariate survival data from a multicentre cancer clinical trial.
22229246 - Clinical experience with thalidomide and lenalidomide in multiple myeloma.
19648826 - Accuracy and complexities of using automated clinical data for capturing chemotherapy a...
11768566 - Practical management of hepatocellular carcinoma.
1407606 - Malignant tumors of the anterior cranial skull base.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Chinese journal of cancer     Volume:  29     ISSN:  1000-467X     ISO Abbreviation:  Chin J Cancer     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-28     Completed Date:  2012-02-16     Revised Date:  2013-02-12    
Medline Journal Info:
Nlm Unique ID:  101498232     Medline TA:  Chin J Cancer     Country:  China    
Other Details:
Languages:  eng     Pagination:  959-63     Citation Subset:  IM    
Department of Radiation Oncology, the Affiliated Hospital of Hainan Medical College, Haikou, Hainan 570102, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use
Carcinoma, Squamous Cell / pathology,  therapy*
Chemoradiotherapy* / adverse effects
Chemotherapy, Adjuvant
Cisplatin / adverse effects,  therapeutic use
Diarrhea / chemically induced,  etiology
Dose Fractionation
Middle Aged
Neoplasm Staging
Quality of Life
Remission Induction
Survival Rate
Taxoids / adverse effects,  therapeutic use
Uterine Cervical Neoplasms / pathology,  therapy*
Vomiting / chemically induced,  etiology
Reg. No./Substance:
0/Taxoids; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The recruitment of exogenous endothelial progenitor cells in lung tumor model of nude mice.
Next Document:  Primary malignant bone neoplasm: a case report of dedifferentiated chondrosarcoma in the rib and rev...